bioAffinity Technologies Welcomes Peter S. Knight to Board of Directors
SAN ANTONIO, May 14, 2018 (GLOBE NEWSWIRE) -- bioAffinity Technologies, a privately held biomedical company advancing breakthrough cancer diagnostics and therapeutics, is pleased to welcome Peter S. Knight, founding partner of Generation Investment Management, to its Board of Directors.
Knight and his partners, former Vice President Al Gore and David Blood, founded Generation Investment Management, a leading global sustainable investing firm with assets under management exceeding $18 billion. Until his retirement in December 2017, Knight oversaw the firm’s US business and participated in its philanthropic work and advocacy for sustainable capitalism. Prior to founding Generation, Knight was a Managing Director of Met West Financial, a California-based asset management company.
“Peter’s experience and expertise is a tremendous asset as we move to commercialize bioAffinity’s non-invasive test for the early detection of lung cancer and develop other life-saving diagnostics and therapeutics,” said bioAffinity President and Chief Executive Officer Maria Zannes.
Knight was general counsel of Medicis Pharmaceutical before opening a law practice which included the International Olympic Committee, the US Olympic Committee and numerous Fortune 500 companies as clients. He started his career at the Antitrust Division of the US Department of Justice and later served as Chief of Staff to Al Gore in both the House of Representatives and the Senate. Knight also served in senior positions on four presidential campaigns, including campaign manager for President Bill Clinton’s 1996 re-election campaign.
“As our scientific team continues to push our technology platform forward, the Board is well positioned to provide the strategic leadership and support that will help us get to market with products that save lives by diagnosing and treating cancer,” said Board Chairman Steve Girgenti. “We are delighted to welcome Peter to the bioAffinity Board.”
Knight has extensive board experience including serving as a Director for Medicis, Par Pharmaceutical, Entremed (Casi), Healthworld, Whitman Education, Comsat and the Schroder Mutual Fund Board complex. He currently serves on the Fund Boards of Generation Investment Management and on the Board of Gratitude Railroad. His philanthropic efforts include serving as Chair of the Climate Museum and the Board of the Friends of Katahdin Woods and Waters, which supports the Katahdin Woods and Waters National Monument in Maine. He received a BA from Cornell University and a JD from the Georgetown Law School.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. (www.bioaffinitytech.com) is a privately held company that develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. Research and optimization of its platform technology is conducted in bioAffinity Technologies’ laboratories and at the University of Texas San Antonio. The Company’s initial product is CyPath® Lung, a diagnostic assay for the detection of early-stage lung cancer.
Contact: Maria Zannes, 505.400.9747
Released May 14, 2018